Clinical Research Directory

Inclusion Criteria: * Symptomatic MPE visible with bedside ultrasound * Histologically or cytologically verified malignancy * Status CT-scan not older than four weeks * MPE requiring at least one drainage procedure * Drained ≥ 14 days before the first PITAC directed treatment * Bidirectional systemic chemotherapy or immunotherapy ≥ 14 days before the first PITAC directed treatment or no simultaneous systemic chemotherapy or immunotherapy * ECOG Performance status 0-2 * Life expectancy ≥ 3 months * Age ≥ 18 years * Danish-speaking and reading patients * Written informed consent according to the local Ethics Committee requirements Exclusion Criteria: * A history of allergic reaction to cisplatin or other platinum containing compounds or doxorubicin * Renal impairment, defined as GFR \< 40 ml/min (Cockcroft-Gault Equation) * Myocardial insufficiency, defined as NYHA class \> 2 * Impaired liver function defined as bilirubin ≥1.5 * Fertility, pregnancy and lactation: Female subjects will be considered of non-reproductive potential if they are either a, b or c: 1. postmenopausal (defined as at least 12 months with no menses without an alternative medical cause; in women \< 45 years of age a high follicle stimulating hormone (FSH) level in the postmenopausal range may be used to confirm a post-menopausal state in women not using hormonal contraception or hormonal replacement therapy. In the absence of 12 months of amenorrhea, a single FSH measurement is insufficient. 2. have had a hysterectomy and/or bilateral oophorectomy, bilateral salpingectomy or bilateral tubal ligation/occlusion, at least 6 weeks prior to screening. 3. have a congenital or acquired condition that prevents childbearing. Previous intrathoracic chemotherapy, intrathoracic antibody treatment or chemical pleurodesis * Any other condition or therapy, which in the investigator´s opinion may pose a risk to the patient or interfere with the study objects